Last reviewed · How we verify
NCT03800069
Validation of Point of Care Liver Function Tests
trial testing Group K Diagnostic point of care device in Liver Diseases in 68 participants. Terminated before completion.
30 May 2019
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 68 |
| Start date | 3 December 2018 |
| Primary completion | 30 May 2019 |
| Estimated completion | 30 May 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Group K Diagnostic point of care device
Conditions studied
- Liver Diseases — all drugs for Liver Diseases →
- Healthy — all drugs for Healthy →
- Cirrhosis, Liver — all drugs for Cirrhosis, Liver →
- Fibrosis — all drugs for Fibrosis →
Sponsor
University of Pennsylvania
Who can join
18 and older, any sex, with Liver Diseases or Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is testing the accuracy of a point of care device that tests liver function within 20 minutes. The target population will be any adult who had liver function tests ordered and to be drawn on the same day as enrollment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03800069
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Diseases
Currently open trials in the same condition.
- NCT07400289 — Development of a FibroScan Liver Examination Using a Single Probe · NA · recruiting
- NCT07150624 — The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine · Phase 4 · recruiting
- NCT06871111 — The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial · Phase 1 · recruiting
- NCT06874296 — Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time · NA · recruiting
- NCT07053488 — CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection · Phase 1, PHASE2 · recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03800069 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 4 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03800069.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing